The Philip Lab studies immune system interactions with cancers. We use genetically-engineered mouse models to track tumor-specific T cells as they differentiate in \u00a0developing tumors (pre-malignant lesions). We make use of high-throughput population-level and single cell RNA-sequencing to capture the transcriptional activity of tumor-specific T cells over time, and we determine the differentiation state using novel epigenetic analyses including ATAC-Seq.<\/p>\n
Tumor-specific T cells are often found in patients’ tumors, however the tumors grow unimpeded; thus the T cells have been rendered dysfunctional. The overall goal of out laboratory is to understand how tumor-specific T cells become dysfunctional, and to devise new strategies to make T cells resistant to dysfunction so they can be used for cancer immunotherapy.<\/p>\n
To learn more about our research, read our recent paper in Nature\u00a0545,\u00a0452\u2013456\u00a0(25 May 2017)\u00a0doi:10.1038\/nature22367:<\/p>\n
http:\/\/www.nature.com\/nature\/journal\/v545\/n7655\/full\/nature22367.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The Philip Lab studies immune system interactions with cancers. We use genetically-engineered mouse models to track tumor-specific T cells as they differentiate in \u00a0developing tumors (pre-malignant lesions). We make use of high-throughput population-level and single cell RNA-sequencing to capture the … Continue reading